Praxis, FDA agree on pivotal trial changes for encephalopathy asset elsunersen
Source: SeekingAlpha
2025-12-09 21:51:49 ET
More on Praxis Precision Medicines
- Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026
- Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET
- Praxis Precision Medicines, Inc. (PRAX) Discusses Essential3 Program and Statistical Modeling Approaches in Clinical Studies Transcript
- Praxis Precision Medicines drops after Culper Research short call
- Praxis a new buy at BTIG as biotech is a top pick for 2026
Read the full article on Seeking Alpha
For further details see:
Praxis, FDA agree on pivotal trial changes for encephalopathy asset elsunersen
Praxis Precision Medicines Inc.
NASDAQ: PRAX
PRAX Trading
-0.96% G/L:
$297.645 Last:
239,843 Volume:
$303.37 Open:
PRAX Latest News
March 13, 2026 10:34:56 am
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline
March 13, 2026 09:43:25 am
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings
March 09, 2026 09:54:00 am
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment
March 04, 2026 04:01:00 pm
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAX Stock Data
$8,057,264,446
20,105,683
0.7%
83
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
